Targeting the Warburg effect may involve a variety of molecular agents; for example, PRL-3, a phosphate agent that may enhance oxidative phosphorylation and ATP production, and FOXM1, a suppressor of MM cell growth, offering potential therapeutic strategies [116]. The gene discussed is FOXM1; the disease is Miyoshi myopathy.